This brand name is authorized in Malta, Poland
The drug REMESTYP contains one active pharmaceutical ingredient (API):
|
1
Terlipressin
UNII 7Z5X49W53P - TERLIPRESSIN
|
|
Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H01BA04 | Terlipressin | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01B Posterior pituitary lobe hormones → H01BA Vasopressin and analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MT | Medicines Authority | Identifier(s): AA565/84401 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100198074 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
